Safety

Vidaza (azacitidine) for Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

December 2015

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Necrotizing fasciitis (including fatal cases)

 

January 2014

Summary View

5 WARNINGS AND PRECAUTIONS

5.3 Renal Abnormalities
  • Deleted the statement, “Safety and effectiveness of VIDAZA in patients with MDS and renal impairment have not been studied as these patients were excluded from the clinical trials.”

8 USE IN SPECIFIC POPULATIONS

8.8 Renal Impairment

new section added

  • Severe renal impairment has no major effect on the PK exposure of azacitidine after single and multiple SC administrations. Therefore, azacitidine can be administered to subjects with renal impairment without initial dose adjustment [see Clinical Pharmacology (12.3)

 

January 2012

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • tumor lysis syndrome, injection site necrosis,and Sweet’s syndrome (acute febrile neutrophilic dermatosis) ....added
     

 

Page Last Updated: 01/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English